Of the last century 90's, an epidemiological survey shows that middle-aged males in pastoral areas of the ratio of benign prostatic hyperplasia than cities, so as to come eat red meat is not conducive to prostate health conclusions. The pathogenesis of benign prostatic hyperplasia studies and there is no final conclusion, but the incidence of the disease increased with age and gradually increased over the age of 50 accounted for 50%, over the age of 80 is almost 100%.
Although men with benign prostatic hyperplasia is a physiological phenomenon of natural aging, but because of its serious impact on quality of life of older men, it is worth attention old friends and to give a positive treatment and drug treatment Guizaijianchi. For patients with mild symptoms generally adopted watchful waiting treatment, moderate and severe symptoms will carry out medical treatment or surgery.
Finasteride 1 5α-reductase inhibitor class, is currently the treatment of benign prostatic hyperplasia ideal commonly used drugs can effectively reduce the enlarged prostate volume, significantly improve patient difficulties in urinating, increased urine flow rate, reduction of acute urinary retention and related operations occur, so as to achieve both the root causes of benign prostatic hyperplasia results. In addition, α-adrenergic blockers can also improve symptoms of urinary obstruction can be the beginning of drug treatment with finasteride class of 5α-reductase inhibitor used in combination to achieve maximum synergy, in particular, in improving urinary frequency, urgency and other symptoms of lower urinary tract. There are also clinical data to prove that 5α-reductase inhibitor and a blocker combination therapy of benign prostatic hyperplasia after 6 months out a blocker for the IPSS <19 patients with disabling symptoms after a blocking anti-jump probability is low, 91% of patients with stable efficacy. Therefore, these patients could be considered the treatment of 6-9 months after the disabled a blocker.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment